Executive Director of the Coalition for Healthcare Communication, a drug-marketing group with offices in New York City and Washington, DC. He is also of counsel with the law firm Wiley Rein LLP, and is a well-known advocate for First Amendment rights of individuals and corporations.
Thomas Abrams is the Director of the Office of Prescription Drug Promotion (OPDP), Food and Drug Administration. Before becoming Director of OPDP, Mr. Abrams was Director of the Division of Drug Marketing, Advertising, and Communications.
Dr. Stockbridge has spent over 15 years in advertising and promotional labeling review, both in CDER’s DDMAC and CBER’s APLB. She is a recognized subject matter expert within the Agency and continues to serve on taskforces and special projects.
Description
FDA enforcement actions need to be understood by every company because they reflect FDA's priorities and concerns in regulating advertising and promotion. In this session, FDA professionals will examine the latest agency enforcement actions and what they mean.
Learning Objectives: Describe the latest FDA enforcement actions in the area of advertising and promotion Explain what the enforcement actions reflect about FDA policies and priorities.